Back to Search

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

  • Protocol Number: 202404074
  • Principal Investigator: Aranha, Olivia
  • Cancer Types: Gastrointestinal

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator’s choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Protocol Interventions

Drug: Placebo, Drug: Capecitabine, Drug: Gemcitabine/Cisplatin, Drug: S-1 [Tegafur/Oteracil/gimeracil]